<DOC>
	<DOCNO>NCT01847677</DOCNO>
	<brief_summary>Recently result show Bevacizumab active monotherapy combination therapy patient ovarian cancer . One objectives evaluate whether addition neoadjuvant bevacizumab improve response whether affect evolution patient .</brief_summary>
	<brief_title>Neoadjuvant Therapy Advanced Ovarian Cancer With Avastin</brief_title>
	<detailed_description>Epithelial ovarian cancer ( OC ) fourth lead cause cancer death woman , lung , breast colon cancer , represent common cause death gynaecological malignancy . The high mortality associate OC due lack screening test enable early diagnosis , thus majority patient diagnose advanced stage disease chance cure limit . In fact , 5-year overall survival ( OS ) rate stage III-IV OC exceed 20-30 % many series . The standard treatment advance OC maximal cytoreductive surgery ( debulking ) follow administration 6 cycle adjuvant chemotherapy carboplatin paclitaxel . In recent year , number study carry antiangiogenic drug . Specifically , bevacizumab , anti-VEGF monoclonal antibody , show active monotherapy combination therapy patient OC receive multiple previous line chemotherapy . One objectives evaluate whether addition neoadjuvant bevacizumab improve response whether affect evolution patient .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Women 18 year old 2 . Obtained informed consent , write sign 3 . Histological confirmation primary peritoneal carcinoma fallopian tube carcinoma 4 . Planned interval debulking surgery 5 . ECOG:0 2 6 . Life expectancy &gt; 12 week 1 . Nonepithelial ovarian cancer , include malignant mixed Müllerian tumor . 2 . Borderline ovarian tumor . 3 . Administration intraperitoneal chemotherapy plan . 4 . Previous systemic antitumor treatment ovarian cancer . 5 . Intestinal obstruction subocclusion , intestinal infiltration show CT scan rectosigmoid infiltration gynaecological examination . 6 . Uncontrolled hypertension . 7 . Any previous radiotherapy : abdomen pelvis . 8 . Major traumatic injury 4 week prior first potential dose bevacizumab . 9 . History clinical suspicion brain metastasis spinal cord compression . 10 . History evidence central nervous system ( CNS ) disorder , unless properly treat standard medical treatment . 11 . Cerebrovascular accident ( CVA ) , transient ischemic attack ( TIA ) subarachnoid haemorrhage ( SAH ) 6 month prior randomization . 12 . Fertile woman childbearing age willing use effective contraception study least 6 month study . 13 . Women breastfeed pregnant . 14 . Prior exposure mouse CA125 antibody . 15 . Treatment experimental product , participation another clinical trial within 30 day prior inclusion . 16 . Malignant tumor ovarian cancer within 5 year prior randomisation , exception cervical carcinoma situ treat correctly and/or basalcell carcinoma . 17 . Known hypersensitivity bevacizumab excipients ( include Cremophor ) . 18 . Nonhealing wound , active peptic ulcer bone fracture . Patients heal incised granuloma secondary intention , evidence fascial dehiscence infection include , require three week wind control . 19 . History evidence bleed thrombotic diathesis 20 . Current recent continue use aspirin &gt; 325 mg / day ( within 10 day prior randomization ) 21 . Current recent use ( within 10 day first cycle treatment ) full dose anticoagulant thrombolytic administer orally parenterally therapeutic purpose ( except vascular permeability , case INR keep 1.5 ) . 22 . Clinically significant cardiovascular disease , include : Myocardial infarction unstable angina ( ≤ 6 month randomization ) Congestive heart failure ( CHF ) class ≥ II NYHA ( New York Heart Association ) Poorly control cardiac arrhythmia despite medication ( may include patient atrial fibrillation control frequency ) Peripheral vascular disease ≥ grade 3 ( i.e . symptomatic interfering activity daily live [ ADL ] need repair review ) 23 . Preexisting sensory motor neuropathy , ≥ grade 2 24 . Demonstration neurological metabolic dysfunction involve reasonable suspicion existence disease condition contraindicate use experimental drug , involve increase risk patient treatmentrelated complication 25 . No medical psychiatric illness may impede performance systemic surgical treatment 26 . Laboratory : Inadequate bone marrow function : ANC : &lt; 1.5 x 109/l platelet count &lt; 100 x 109/l Hb &lt; 9 g/dl . ( Patients may transfuse ) Inadequate coagulation parameter : Activated partial thromboplastin time ( APTT ) &gt; 1.5 x ULN INR &gt; 1.5 Inadequate liver function , define : Serum ( total ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) institution AST &amp; ALT &gt; 2.5 x ULN ( &gt; 5 x ULN patient liver metastasis ) alkaline phosphatase &gt; 2.5 x ULN ( &gt; 5 x ULN case liver metastases &gt; 10 x ULN case bone metastasis ) . Inadequate renal function , define : Serum creatinine &gt; 2.0 mg/dl &gt; 177 mol/l Urine dipstick proteinuria &gt; 2+ Patients 2+ proteinuria baseline dipstick analysis undergo 24hour urine collection must demonstrate ≤1g protein 24hour urine collection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>neoadyuvant</keyword>
	<keyword>bevacizumab</keyword>
</DOC>